<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33411">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837719</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-511</org_study_id>
    <nct_id>NCT01837719</nct_id>
  </id_info>
  <brief_title>Bioequivalence (BE) Study of Individual Atazanavir and Cobicistat Compared to Atazanavir in Fixed Dose Combination With Cobicistat</brief_title>
  <acronym>AtazanavirBE</acronym>
  <official_title>A Randomized, 5-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Atazanavir When Co-Administered With Cobicistat as a Fixed Dose Combination Relative to the Single Agents Following a Light Meal, the Relative Bioavailability of Atazanavir When Co-Administered With Cobicistat as a Fixed Dose Combination Relative to the Single Agents Under Fasted Conditions, and the Effect of Food on the Bioavailability of Atazanavir in the Fixed Dose Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the comparability of Atazanavir in a fixed dose
      combination with Atazanavir co-administered with Cobicistat as single agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose:  Atazanavir is a marketed product and this study is to evaluate the
      single-dose pharmacokinetics and bioequivalence of Atazanavir when administered as a fixed
      dose combination relative to the commercial capsule formulation, co-administered with
      Cobicistat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Systemic exposure to Atazanavir (ATV) measured as maximum observed plasma concentration (Cmax)</measure>
    <time_frame>11 timepoints on Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposure to ATV measured as Cmax</measure>
    <time_frame>11 timepoints on Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposure to ATV measured as area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>11 timepoints on Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposure to ATV measured as AUC(0-T)</measure>
    <time_frame>11 timepoints on Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposure to ATV measured as area under the plasma concentration-time curve from time zero extrapolated to infinity [AUC(INF)]</measure>
    <time_frame>11 timepoints on Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposure to ATV measured as AUC(INF)</measure>
    <time_frame>11 timepoints on Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be measured by incidence of adverse events (AEs), serious AEs, AEs leading to discontinuations and deaths, and marked abnormalities in clinical laboratory tests, vital signs and electrocardiogram (ECG) measurements</measure>
    <time_frame>On Day 24 or 31</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of ATV</measure>
    <time_frame>11 timepoints on Days 1, 8, 15, 22 and 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T) of ATV</measure>
    <time_frame>11 timepoints on Days 15, 22 and 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentration at 24 hour (C24) after ATV dose</measure>
    <time_frame>11 timepoints on Days 1, 8, 15, 22 and 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (T-HALF) of ATV</measure>
    <time_frame>11 timepoints on Days 1, 8, 15, 22 and 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ATV</measure>
    <time_frame>11 timepoints on Days 15, 22 and 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF) of ATV</measure>
    <time_frame>11 timepoints on Days 15, 22 and 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Cobicistat</measure>
    <time_frame>12 timepoints on 1, 2, 8, 9, 15, 16, 22 23, 29 and 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Cobicistat</measure>
    <time_frame>12 timepoints on 1, 2, 8, 9, 15, 16, 22 23, 29 and 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T) of Cobicistat</measure>
    <time_frame>12 timepoints on 1, 2, 8, 9, 15, 16, 22 23, 29 and 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF) of Cobicistat</measure>
    <time_frame>12 timepoints on 1, 2, 8, 9, 15, 16, 22 23, 29 and 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALF of Cobicistat</measure>
    <time_frame>12 timepoints on 1, 2, 8, 9, 15, 16, 22 23, 29 and 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Human Immunodeficiency Virus Type 1 (HIV-1)</condition>
  <arm_group>
    <arm_group_label>Arm A: Atazanavir + Cobicistat co-administered</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of single dose of Atazanavir 300 mg capsule and Cobicistat 150 mg tablet given by mouth following a light meal on Days 1, 8, 15, 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of single fixed dose of combination of Atazanavir 300 mg capsule / Cobicistat 150 mg tablet given by mouth following a light meal on Days 1, 8, 15, 22 and 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Atazanavir + Cobicistat co-administered</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of single dose of Atazanavir 300 mg capsule and Cobicistat 150 mg tablet given by mouth under fasted conditions on Days 1, 8, 15 and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of single fixed dose of combination of Atazanavir 300 mg capsule / Cobicistat 150 mg tablet given by mouth under fasted conditions on Days 1, 8, 15, 22 and 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of single fixed dose of combination of Atazanavir 300 mg capsule / Cobicistat 150 mg tablet given by mouth following a high fat meal on Days 1, 8, 15, 22 and 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <arm_group_label>Arm A: Atazanavir + Cobicistat co-administered</arm_group_label>
    <arm_group_label>Arm B: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <arm_group_label>Arm C: Atazanavir + Cobicistat co-administered</arm_group_label>
    <arm_group_label>Arm D: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <arm_group_label>Arm E: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <other_name>BMS-232632</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobicistat</intervention_name>
    <arm_group_label>Arm A: Atazanavir + Cobicistat co-administered</arm_group_label>
    <arm_group_label>Arm B: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <arm_group_label>Arm C: Atazanavir + Cobicistat co-administered</arm_group_label>
    <arm_group_label>Arm D: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
    <arm_group_label>Arm E: Atazanavir/Cobicistat fixed dose combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women of ages 18 to 49 and BMI 18 to 32 kg/m2, inclusive

          -  Women of childbearing potential (WOCBP) must not be pregnant or breastfeeding

          -  WOCBP and men who are sexually active with WOCBP must use acceptable contraceptive
             methods

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Any of the following on 12-lead electrocardiogram (ECG) prior to study drug
             administration, confirmed by repeat

               1. PR ≥210 msec

               2. QRS ≥120 msec

               3. QT ≥500 msec

               4. QTcF ≥450 msec

          -  Positive urine screen for drugs of abuse

          -  Second or third degree A-V block or clinically relevant ECG abnormalities

          -  Any of the following laboratory results outside of the ranges specified below:

               1. Alanine aminotransferase (ALT) &gt;upper limit of normal (ULN)

               2. Aspartate aminotransferase (AST) &gt;ULN

               3. Total bilirubin &gt;ULN

               4. Serum creatinine &gt;ULN

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or
             HIV-1, -2 antibodies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ppd Development, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atazanavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
